R03HL177034
Project Grant
Overview
Grant Description
Identifying inflammatory and endothelial mechanisms promoting cardiac deformation in women with a history of preeclampsia - Project summary
Women with a history of preeclampsia (PREE) are at a 2-fold higher risk of cardiovascular disease and develop subclinical cardiovascular disease 5 years earlier than women with normotensive pregnancies; however, the mechanism remains unknown.
In our K23 study of 150 participants including 90 with history of preeclampsia and 60 with normotensive pregnancy 2-10 years postpartum, we found evidence of subclinical cardiovascular disease (myocardial deformation and vascular dysfunction) in those with history of PREE.
Our central hypothesis is that women with a history of preeclampsia will demonstrate long-term elevations in biomarkers of inflammation and endothelial dysfunction and that these will be directly associated with the observed subclinical cardiovascular disease.
Utilizing the K23 biorepository of 150 samples, we will measure levels of inflammatory cytokines, endothelial biomarkers and endothelial microvesicles.
We will then examine the relationship of these biomarkers to measurements of myocardial deformation (CMRI) and vascular functional (EndoPAT and SphygmoCor).
Upon completion of these aims, we expect to establish endothelial dysfunction and chronic inflammation as the mechanisms responsible for the myocardial deformation and vascular dysfunction in women with history of preeclampsia 2-10 years postpartum.
These insights will significantly advance our understanding of these mechanisms and guide future pharmacological interventions.
Women with a history of preeclampsia (PREE) are at a 2-fold higher risk of cardiovascular disease and develop subclinical cardiovascular disease 5 years earlier than women with normotensive pregnancies; however, the mechanism remains unknown.
In our K23 study of 150 participants including 90 with history of preeclampsia and 60 with normotensive pregnancy 2-10 years postpartum, we found evidence of subclinical cardiovascular disease (myocardial deformation and vascular dysfunction) in those with history of PREE.
Our central hypothesis is that women with a history of preeclampsia will demonstrate long-term elevations in biomarkers of inflammation and endothelial dysfunction and that these will be directly associated with the observed subclinical cardiovascular disease.
Utilizing the K23 biorepository of 150 samples, we will measure levels of inflammatory cytokines, endothelial biomarkers and endothelial microvesicles.
We will then examine the relationship of these biomarkers to measurements of myocardial deformation (CMRI) and vascular functional (EndoPAT and SphygmoCor).
Upon completion of these aims, we expect to establish endothelial dysfunction and chronic inflammation as the mechanisms responsible for the myocardial deformation and vascular dysfunction in women with history of preeclampsia 2-10 years postpartum.
These insights will significantly advance our understanding of these mechanisms and guide future pharmacological interventions.
Awardee
Funding Goals
TO FOSTER HEART AND VASCULAR RESEARCH IN THE BASIC, TRANSLATIONAL, CLINICAL AND POPULATION SCIENCES, AND TO FOSTER TRAINING TO BUILD TALENTED YOUNG INVESTIGATORS IN THESE AREAS, FUNDED THROUGH COMPETITIVE RESEARCH TRAINING GRANTS. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO STIMULATE TECHNOLOGICAL INNOVATION, USE SMALL BUSINESS TO MEET FEDERAL RESEARCH AND DEVELOPMENT NEEDS, FOSTER AND ENCOURAGE PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY SOCIALLY AND ECONOMICALLY DISADVANTAGED PERSONS, AND INCREASE PRIVATE-SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE TECHNOLOGICAL INNOVATION, FOSTER TECHNOLOGY TRANSFER THROUGH COOPERATIVE R&D BETWEEN SMALL BUSINESSES AND RESEARCH INSTITUTIONS, AND INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL R&D.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Cincinnati,
Ohio
452192906
United States
Geographic Scope
Single Zip Code
The Christ Hospital was awarded
Project Grant R03HL177034
worth $99,150
from National Heart Lung and Blood Institute in January 2025 with work to be completed primarily in Cincinnati Ohio United States.
The grant
has a duration of 1 year 10 months and
was awarded through assistance program 93.837 Cardiovascular Diseases Research.
The Project Grant was awarded through grant opportunity Limited Competition: Small Grant Program for NHLBI K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional).
Status
(Ongoing)
Last Modified 1/6/25
Period of Performance
1/1/25
Start Date
11/30/26
End Date
Funding Split
$99.2K
Federal Obligation
$0.0
Non-Federal Obligation
$99.2K
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
R03HL177034
SAI Number
R03HL177034-3208652546
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Awarding Office
75NH00 NIH NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
Funding Office
75NH00 NIH NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
Awardee UEI
EK4SMPJKY5E4
Awardee CAGE
5A7K8
Performance District
OH-01
Senators
Sherrod Brown
J.D. (James) Vance
J.D. (James) Vance
Modified: 1/6/25